DiagnoCure Directors Re-Elected by Shareholders at Annual and Special Meeting of Shareholders
QUEBEC CITY, April 29, 2013 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) is pleased to announce that Dr. Yves Fradet, Dr. Louise Proulx, Mr. Andrew Sheldon, Dr. Jacques Simoneau, and Dr. Vincent R. Zurawski, were re-elected by shareholders at the 2013 annual and special meeting of shareholders, held today in Montreal.
Shareholders also reappointed Ernst & Young as auditors of the company, approved and ratified amendments to the articles of DiagnoCure, approved and ratified the new by-laws of the company - including the advanced notice by-law, and approved all unallocated options under DiagnoCure's stock option plan.
Dr. Yves Fradet, Chairman of the Board stated, "We appreciate the support of our shareholders in re-electing all of DiagnoCure's director nominees. Rest assured, your board and management team will continue to work to enhance and maximize value for shareholders."
"We will continue to be receptive to feedback from all of our shareholders." said Dr. Fradet.
The election results for the Board of directors are as follows:
| | For | Withheld |
| DiagnoCure nominees | | |
| Yves Fradet | 15,064,450 | 11,584,571 |
| Louise Proulx | 15,195,476 | 11,573,041 |
| Andrew J. Sheldon | 15,155,676 | 11,612,841 |
| Jacques Simoneau | 15,194,976 | 11,573,041 |
| Vincent R. Zurawski | 15,167,576 | 11,600,941 |
| | | |
| Dissident nominees | | |
| Pierre Dozois | 5,385,250 | 22,797,322 |
| Paul Guay | 5,385,250 | 22,797,322 |
| Hans Mäder | 5,385,250 | 22,797,322 |
| | | |
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, please visit www.diagnocure.com.